CN1500491A - 口服罗红霉素控释制剂 - Google Patents
口服罗红霉素控释制剂 Download PDFInfo
- Publication number
- CN1500491A CN1500491A CNA021487480A CN02148748A CN1500491A CN 1500491 A CN1500491 A CN 1500491A CN A021487480 A CNA021487480 A CN A021487480A CN 02148748 A CN02148748 A CN 02148748A CN 1500491 A CN1500491 A CN 1500491A
- Authority
- CN
- China
- Prior art keywords
- roxithromycin
- acid
- weight
- oral
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 title claims abstract description 58
- 229960005224 roxithromycin Drugs 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title description 10
- 238000009472 formulation Methods 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 18
- 229930006000 Sucrose Natural products 0.000 claims abstract description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 235000010355 mannitol Nutrition 0.000 claims abstract description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 13
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 12
- 229920000178 Acrylic resin Polymers 0.000 claims abstract description 12
- 229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 5
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 21
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 21
- 239000003405 delayed action preparation Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 229960003943 hypromellose Drugs 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- -1 inorganic acid salt Chemical class 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 abstract description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 37
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229940047998 roxithromycin 300 mg Drugs 0.000 description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920006184 cellulose methylcellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBCAVSYHPPARHX-UHFFFAOYSA-M n'-cyclohexyl-n-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]methanediimine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1CCCCC1N=C=NCC[N+]1(C)CCOCC1 GBCAVSYHPPARHX-UHFFFAOYSA-M 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
8h | 74.1±4.19 | 46.0±2.81 | 64.6±1.00 | 71.5±2.19 | 87.9±2.82 |
12h | 88.8±4.67 | 60.6±2.71 | 84.4±1.86 | 87.6±1.70 | 97.3±0.99 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021487480A CN100336511C (zh) | 2002-11-15 | 2002-11-15 | 口服罗红霉素控释制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021487480A CN100336511C (zh) | 2002-11-15 | 2002-11-15 | 口服罗红霉素控释制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1500491A true CN1500491A (zh) | 2004-06-02 |
CN100336511C CN100336511C (zh) | 2007-09-12 |
Family
ID=34233310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021487480A Expired - Fee Related CN100336511C (zh) | 2002-11-15 | 2002-11-15 | 口服罗红霉素控释制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100336511C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552172A (zh) * | 2012-03-21 | 2012-07-11 | 广州共禾医药科技有限公司 | 一种罗红霉素控释制剂及其制备方法 |
CN105412037A (zh) * | 2015-12-30 | 2016-03-23 | 西安德天药业股份有限公司 | 一种罗红霉素缓控释制剂 |
CN106580903A (zh) * | 2016-11-17 | 2017-04-26 | 江苏豪森药业集团有限公司 | 罗红霉素缓释药物组合物 |
CN106727394A (zh) * | 2017-01-17 | 2017-05-31 | 淮阴工学院 | 应用磷酸化多孔木薯淀粉制备罗红霉素缓释片的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229141B (zh) * | 2008-02-29 | 2010-07-07 | 常州制药厂有限公司 | 一种阿司匹林缓释片及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0995440A (ja) * | 1995-09-29 | 1997-04-08 | Roussel Morishita Kk | 徐放性製剤およびその製造方法 |
SI20108B (en) * | 1997-06-11 | 2001-12-31 | Abbott Lab | A controlled release formulation for poorly soluble basic drugs |
-
2002
- 2002-11-15 CN CNB021487480A patent/CN100336511C/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552172A (zh) * | 2012-03-21 | 2012-07-11 | 广州共禾医药科技有限公司 | 一种罗红霉素控释制剂及其制备方法 |
CN102552172B (zh) * | 2012-03-21 | 2013-03-20 | 广州共禾医药科技有限公司 | 一种罗红霉素控释制剂及其制备方法 |
CN105412037A (zh) * | 2015-12-30 | 2016-03-23 | 西安德天药业股份有限公司 | 一种罗红霉素缓控释制剂 |
CN105412037B (zh) * | 2015-12-30 | 2018-08-28 | 西安远大德天药业股份有限公司 | 一种罗红霉素缓控释制剂 |
CN106580903A (zh) * | 2016-11-17 | 2017-04-26 | 江苏豪森药业集团有限公司 | 罗红霉素缓释药物组合物 |
CN106580903B (zh) * | 2016-11-17 | 2019-12-13 | 江苏豪森药业集团有限公司 | 罗红霉素缓释药物组合物 |
CN106727394A (zh) * | 2017-01-17 | 2017-05-31 | 淮阴工学院 | 应用磷酸化多孔木薯淀粉制备罗红霉素缓释片的方法 |
CN106727394B (zh) * | 2017-01-17 | 2019-08-30 | 淮阴工学院 | 应用磷酸化多孔木薯淀粉制备罗红霉素缓释片的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100336511C (zh) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1142780C (zh) | 药用组合物 | |
CN1278678C (zh) | 具有高生物利用率的非诺贝特药物组合物及其制备方法 | |
CN1589139A (zh) | 调节释放坦洛新片剂 | |
CN1297274C (zh) | 药物组合物 | |
CN1564684A (zh) | 药物组合物 | |
CN1747723A (zh) | 含活性成分混合物的组合物及其制备方法 | |
CN1762357A (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
CN1682719A (zh) | 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法 | |
CN1799543A (zh) | 替米沙坦分散片及其制备方法 | |
CN1903182A (zh) | 小型化盐酸沙格雷酯经口给药制剂 | |
CN100336511C (zh) | 口服罗红霉素控释制剂 | |
CN1684681A (zh) | 比西发定制剂 | |
CN1965817A (zh) | 一种格列本脲缓释片制剂及其制备方法 | |
CN1915216A (zh) | 坦度螺酮及其衍生物的新用途、及含有坦度螺酮的组合物 | |
CN1732953A (zh) | 一种治疗高血压的分散片 | |
CN1264520C (zh) | 一种阿奇霉素肠溶制剂及其制备方法 | |
CN1887277A (zh) | 含有降血脂成分的分散片及其制备方法 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1946376A (zh) | 包衣片剂组合物及其制法 | |
CN1823808A (zh) | 盐酸克林霉素棕榈酸酯分散片及其制备方法 | |
CN1895250A (zh) | 一种格列喹酮的缓释制剂 | |
CN1543943A (zh) | 口服水飞蓟素缓释制剂及其制备方法 | |
CN1835742A (zh) | 控释型盐酸坦索洛新片剂的制备方法及控释型盐酸坦索洛新片剂 | |
CN1433311A (zh) | 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物 | |
CN1552327A (zh) | 口服左氧氟沙星控释药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 222000 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222000 Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: Jiangsu best Pharmaceutical Co.,Ltd. Address after: 222000 Lianyungang economic and Technological Development Zone, Jiangsu Patentee after: Jiangsu best Pharmaceutical Co.,Ltd. Address before: 222000 Lianyungang economic and Technological Development Zone, Jiangsu Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070912 Termination date: 20201115 |